College of Pharmacy at University of Basrah held a discussion session (the use of the drug Emicuzimab in hereditary hemophilia type A) with the participation of researchers and specialists. The lecture given by Dr. Hanan Hamed included an explanation of the hereditary hemorrhagic disease or hemophilia, which is one of the types of bleeding disorders that causes imbalance in the normal blood clotting mechanism and slows the rate of blood clotting, its symptoms, methods of diagnosis and treatments used. The use of the new drug Emicuzimab to prevent or reduce the incidence of bleeding episodes in adult patients and children with hemophilia A. It is the first treatment in its class to be given by subcutaneous injection weekly, and it works by restoring blood clotting to these patients.
